Table 3.

Summary of the different chemotherapy strategies evaluated in PLGGs

Regimen course	Reference	Study length	Number of patients	Eligbility		Response				OS		PFS
				First line	Recurrence/progression	CR (%)	PR (%)	MR/SD (%)	PD (%)	year	%	year	%
CBP-VCR	Packer et al 1993	NA	60	yes	yes	2	37	50	11	NA		NA
	Packer et al 1997	1989–1993	78	yes	yes	5	28	60	6	3	97	3	68
	Demaerel et al 2002	NA	9	yes	no	0	55	45	0	NA		NA
	Gnekow et al 2004	1996–2004	123	yes	no	2	6	76	7	5	87	5	61
	Ronghe M et al 2010	1996–2006	16	yes	yes	6	50	38	6	NA		NA
	Ater et al 2012	1997–2000	137	yes	yes	CR/PR: 35		32	33	5	86	5	39
CBP/VP16 CPP/VCR lomustine/PC/VCR	Bruggers et al 2007	NA	10	yes	yes	20	10	70	0	NA		NA
PC/CBP VP16/CisP VCR/CCP	Laithier et al 2003	1990–1998	85	no	yes	0	42	45	13	5	89	5	34
CBP/VP16	Castello et al 1995	NA	13	yes	no	8	0	70	22	NA		NA
CBP/tamoxifene	Walther et al 2011	NA	13	yes	no	0	15	69	15	3	69	3	47
CBP/vinblastine	Jakackl et al 2011	2006–2008	26	yes	yes	0	5	81	14	NA		NA
CBP or Ibroplatine	Friedman et al 1992	1986–1990	12	yes	yes	0	0	75	25	NA		NA
CisP/VCR	Massimino 2002	1991–2000	34	yes	no	3	32	65	0	3	100	3	78
	Massimino 2010	2001–2007	37	yes	no	0	47	20	33	3	97	3	65
CBP	Moghrabl et al 1993	NA	6	no	yes	0	0	100	0	NA		NA
	Aquino et al 1999	1992–1996	12	no	yes	0	33	50	17	3	83	NA
	Gururangan et al 2002	1993–2000	81	no	yes	2	21	82	15	3	84	3	64
CisP	Hsu et al 2008	1992–2007	16	no	yes	0	25	31	44	5	94	5	56
oxaliplatin	Beaty et al 2010	2004–2006	9	no	yes	0	0	38	62	NA		NA
CisP/VCR	Sawamura et al 2009	1992–2008	15	no	yes	7	53	40	0	NA		NA
VP16-VCR	Pons et al 1992	NA	20	yes	yes	0	0	71	29	NA		NA
VCR/VP16/CPP/5-FU	Lee et al 2006	1999–2004	13	no	yes	8	38	23	31	6	100	6	67
TMZ	Nicholson et al 2007	1998–1999	22	no	yes	0	5	95	0	NA		NA
	Gururangan et al 2007	1999–2005	30	no	yes	0	10	43	47	4	71	4	17
	Khaw et al 2007	1999–2005	13	no	yes	15	23	23	38	NA		3	57
	Bartels et al 2011	2000–2006	28	no	yes	NA	NA	NA	NA	2	71	NA
TPDCV	Prados et al 1997	1984–1992	42	yes	yes	0	36	59	5	5	78	NA
	Mishra et al 2010	1984–1992	33	yes	yes	0	NA	NA	76	15	71	15	23
TPCV	Lancaster et al 2003	NA	10	no	yes	NA	NA	78	NA	NA		NA
	Ater et al 2012	1997–2000	137	yes	yes	CR/PR: 30		36	34	5	87	5	52
BCNU/VCR/MTX-IT	Sumer et al 1978	NA	6	NA	NA	NA	NA	50	NA	NA		NA
vinblastin	Lafaye-Cousin et al 2005	NA	9	no	yes	11	56	22	11	NA		NA
	Bouffet et al 2012	2002–2009	51	no	yes	2	34	38	26	5	93	5	43
CPP	Kadota et al 1999	1996–1997	15	no	yes	7	0	57	36	NA		NA
CBP/VCR VCR/VP16 TPCV vinblastine	Scheinemann et al 2011	1985–2009	38	no	yes	NA	NA	NA	NA	5	86	;	37
bevacizumab/irinotecan	Packer et al 2009	2006–2008	10	no	yes	11	44	45	0	NA		NA
	Coucec et al 2012	2007–2010	11	no	yes	0	63	0	37	NA		NA
nimotuzumab	Saurez et al 2009	2005–2007	4	no	yes	0	0	50	50	NA		NA
erlotinib/rapamycin	Yalon et al 2013	2007–2010	21	no	yes	0	6	35	59	NA		NA
everolimus	Krueger et al 2010	2009–2010	28	no	yes	0	75	25	0	NA		NA

CBP: carboplatin, VCR: vincristine, VP16: etoposide, CPP: cyclophosphamide, PC: procarbazine, CisP: cisplatin, 5-FU: 5-fluorouracile, TMZ: temozolomide, TPDCV: five-drug regimen consisting of 6- thioguanine, procarbazine, dibromodulcitol, 1-(2-chloro- ethyl)-3-cyclohexyl-1-nitrosourea (CCNU), and vincristine, TPCV: thioguanine, procarbazine, lomustine, and vincristine, BCNU: carmustine, MTX-IT: intrathecal injection of methotrexate, CR: complete response, PR: partial response, MR/SD: minor response/stable disease, PD: progressive disease, OS: overall survival, PFS: progression free survival